
QuantumBio Inc Profile last edited on: 5/16/18
CAGE: 39MC9
UEI: SFCDUHJNHBM4
Business Identifier: Computer-assisted molecular modeling and drug design Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
2790 West College Avenue Suite 900a
State College, PA 16801
State College, PA 16801
(814) 235-6908 |
info@quantumbioinc.com |
www.quantumbioinc.com |
Location: Single
Congr. District: 12
County: Centre
Congr. District: 12
County: Centre
Public Profile
QuantumBio, Inc. develops, licenses, and customizes computer-assisted molecular modeling and computer-assisted drug design solutions for pharmaceutical, biotechnology, and life science research organizations. The firm's DivCon Discovery Suite is built on cutting-edge technology utilizing fast, high-performance linear scaling, quantum mechanical algorithms in a user-friendly format. These technologies have been used in Computational Chemistry, X-ray Crystallography, and Nuclear Magnetic resonance to better understand interaction energies, to determine ligand and fragment binding modes, to crystallographically refine X-ray structures leading to experimental structures with lower strain, and to determine ligand and active site protonation states. With these tools, even lower resolution crystal structures become more useful for drug design campaigns.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 2 | NIH | $862,065 | |
Project Title: Research and cloud deployment of enhanced sampling methods in MovableType | ||||
2021 | 2 | NIH | $1,179,542 | |
Project Title: Research and Deployment of Binding-Domain Flexible Movabletype (MTFLEX) for Free Energy-Based Affinity Prediction and Crystallographic Structure Determination | ||||
2019 | 2 | NIH | $1,256,638 | |
Project Title: Development of the Movable Type free energy method for ligand placement in X-ray crystallography | ||||
2016 | 2 | NIH | $1,297,142 | |
Project Title: Development and Deployment of the Movable Type Method for Drug Discovery and DESI | ||||
2015 | 1 | NIH | $141,089 | |
Project Title: A New Approach to Solvent Determination in QM/MM-Based X-Ray Crystallographic Refinement |
Key People / Management
Lance M Westerhoff -- President and General Manager
Oleg Borbulevych -- Scientist
Walter Lovenberg -- Acting Chief Executive Officer
Roger Martin -- Software Engineer
Kenneth M Merz Jr -- Chief Scientific Officer
Oleg Borbulevych -- Scientist
Walter Lovenberg -- Acting Chief Executive Officer
Roger Martin -- Software Engineer
Kenneth M Merz Jr -- Chief Scientific Officer
Company News
There are no news available.